Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 16,841 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions: Essential Amino Acid (EAA) Supplement, Placebo; Dietary Supplement · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Myelodysplastic Syndrome
Interventions: decitabine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 4
States / cities: Canton, Ohio • Woonsocket, Rhode Island • Nashville, Tennessee + 1 more

Conditions: Substance Withdrawal Syndrome
Interventions: Ondansetron and Placebo crossover; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura, Microparticles, Microangiopathic Hemolytic Anemia
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions: NVX-CoV2705 Vaccine; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Austin, Texas

Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: Transcutaneous auricular vagus nerve stimulation, Sham device; Device
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: Tourette Syndrome
Interventions: Valbenazine, Placebo oral capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 48
States / cities: Sun City, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 43 more

Conditions: HIV Infections
Interventions: Indinavir sulfate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more

Conditions: Guillain-Barre Syndrome
Interventions: Peripheral nerve ultrasound, Measurement of strength; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Fetal Alcohol Spectrum Disorders
Interventions: No intervention; Other
Lead sponsor: Indiana University; Other
Eligibility: 1 Month to 110 Years
Enrollment: 751 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Metabolic Syndrome
Interventions: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count; Behavioral
Lead sponsor: Family Medicine Residency of Idaho; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Caldwell, Idaho • Jerome, Idaho • Nampa, Idaho

Conditions: Dysfunctional Tear Syndrome
Interventions: InflammaDry; Device
Lead sponsor: Rapid Pathogen Screening; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Bradenton, Florida • Springfield, Missouri • Johnson City, New York + 1 more

Conditions: Pediatric Feeding Disorder, Chronic, Pediatric Feeding Dysfunction, Acute
Interventions: Parent Acceptance and Commitment Therapy (PACT), Control; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Catheter-Related Infections, Bacteremia
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Gut
Interventions: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized); Drug
Lead sponsor: Marathon Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Cleveland, Ohio + 2 more

Conditions: Neurodegenerative Diseases, sca3, MSA - Multiple System Atrophy, Ataxia, Synucleinopathies
Interventions: 18F-PBR06, 18F-PBR06; Drug · Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: Bronchoscopies and Bronchoalveolar Lavages (BALs), Chest Tomography (CT), Electrocardiogram (ECG), Pulmonary function tests (PFTs), 6 minute walk test (6MWT); Procedure · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions: Not listed
Lead sponsor: Edimer Pharmaceuticals; Industry
Eligibility: Up to 36 Months
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri

Conditions: Human Immunodeficiency Virus
Interventions: Dapivirine; Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
Interventions: Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea; Drug · Procedure · Biological + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
Interventions: CX-01, Azacitidine, Bone marrow biopsy, Peripheral blood draw; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cutaneous T-Cell Lymphoma
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 16
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more

Conditions: Neurofibromatosis Type 1, Cutaneous Neurofibromas
Interventions: Imiquimod 5% Cream; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hemodialysis
Interventions: HeRO Vascular Access Device; Device
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Miami, Florida • Atlanta, Georgia • Springfield, Illinois + 4 more

Search by objective public record fields.

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Effect of Ondansetron for Withdrawal Symptoms

The Role of Microparticles as a Biomarker

A Strain Change Study for SARS-CoV-2 rS Vaccines

taVNS for FRNS in Children

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients

Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome

Dissecting the Genetics of Fetal Alcohol Spectrum Disorders

Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial

Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye

Parent Acceptance and Commitment Therapy (PACT) for Parents of Children With Pediatric Feeding Disorder

Comparison of Infection Rates Among Patients Using Two Catheter Access Devices

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia

Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women

HSCT for High Risk Inherited Inborn Errors

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

HeRO Vascular Access Device Bacteremia Study